Product Name
COLLAGEN III (Col3a1), Polyclonal Antibody
Full Product Name
RABBIT ANTI RAT COLLAGEN III
Product Gene Name
anti-Col3a1 antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P13941
Specificity
This item recognises rat collagen type III, a fibrillar collagen found in extensible connective tissues such as skin, lung, and the vascular system, frequently in association with type I Collagen. This antibody shows less than 10% cross-reactivity with collagen type V and minimal reactivity with rat collagen type I and elastin.
Form/Format
Purified
Purified IgG - liquid
Perservative Stabilisers
0.09% Sodium Azide (NaN3)
Preparation
Immunogen
Purified collagen III from rat skin.
Preparation and Storage
Store at 4 degree C or at -20 degree C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life: 18 months from date of despatch.
Other Notes
Small volumes of anti-Col3a1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-Col3a1 antibody
MBS220766 recognises rat collagen type III, a fibrillar collagen found in extensible connective tissues such as skin, lung, and the vascular system, frequently in association with type I Collagen. This antibody shows less than 10% cross-reactivity with collagen type V and minimal reactivity with rat collagen type I and elastin.
Applications Tested/Suitable for anti-Col3a1 antibody
Immunohistology Frozen, ELISA (EIA), Immunofluorescence (IF), Immunohistology Paraffin, Radioimmunoassays (RIA)
Application Notes for anti-Col3a1 antibody
Immunohistology - Frozen: Minimum Dilution: 1/250; Maximum Dilution: 1/1000;
ELISA: Minimum Dilution: 1/100; Maximum Dilution: 1/400;
Immunofluorescence: Maximum Dilution: 1/80;
Immunohistology - Paraffin: Minimum Dilution: 1/250; Maximum Dilution: 1/1000;
Radioimmunoassays: Minimum Dilution: 1/25; Maximum Dilution: 1/100
NCBI/Uniprot data below describe general gene information for Col3a1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_114474.1
[Other Products]
NCBI GenBank Nucleotide #
NM_032085.1
[Other Products]
UniProt Primary Accession #
P13941
[Other Products]
UniProt Secondary Accession #
O70604; Q5PQT6[Other Products]
UniProt Related Accession #
P13941[Other Products]
Molecular Weight
138,936 Da[Similar Products]
NCBI Official Full Name
collagen alpha-1(III) chain
NCBI Official Synonym Full Names
collagen, type III, alpha 1
NCBI Official Symbol
Col3a1??[Similar Products]
NCBI Protein Information
collagen alpha-1(III) chain; collagen alpha-1(III) chain; procollagen, type III, alpha 1
UniProt Protein Name
Collagen alpha-1(III) chain
UniProt Gene Name
Col3a1??[Similar Products]
UniProt Entry Name
CO3A1_RAT
NCBI Summary for Col3a1
may be involved in craniofacial development [RGD, Feb 2006]
UniProt Comments for Col3a1
CO3A1: Collagen type III occurs in most soft connective tissues along with type I collagen. Defects in COL3A1 are a cause of Ehlers-Danlos syndrome type 3 (EDS3); also known as benign hypermobility syndrome. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS3 is a form of Ehlers-Danlos syndrome characterized by marked joint hyperextensibility without skeletal deformity. Defects in COL3A1 are the cause of Ehlers-Danlos syndrome type 4 (EDS4). EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS4 is the most severe form of the disease. It is characterized by the joint and dermal manifestations as in other forms of the syndrome, characteristic facial features (acrogeria) in most patients, and by proneness to spontaneous rupture of bowel and large arteries. The vascular complications may affect all anatomical areas. Defects in COL3A1 are a cause of susceptibility to aortic aneurysm abdominal (AAA). AAA is a common multifactorial disorder characterized by permanent dilation of the abdominal aorta, usually due to degenerative changes in the aortic wall. Histologically, AAA is characterized by signs of chronic inflammation, destructive remodeling of the extracellular matrix, and depletion of vascular smooth muscle cells. Belongs to the fibrillar collagen family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Cell adhesion; Secreted; Motility/polarity/chemotaxis; Secreted, signal peptide; Extracellular matrix
Cellular Component: extracellular matrix; proteinaceous extracellular matrix; extracellular space; collagen; collagen type III
Molecular Function: integrin binding; platelet-derived growth factor binding; metal ion binding; extracellular matrix structural constituent; SMAD binding
Biological Process: skin development; integrin-mediated signaling pathway; blood vessel development; collagen fibril organization; wound healing; heart development; cell-matrix adhesion; negative regulation of immune response; positive regulation of Rho protein signal transduction; response to radiation; gut development; response to mechanical stimulus; transforming growth factor beta receptor signaling pathway; response to cytokine stimulus; fibril organization and biogenesis; cerebral cortex development; peptide cross-linking; skeletal development; aging
Research Articles on Col3a1
1. Hypoxia alone can upregulate DNA synthesis and expression of collagen type I and III mRNA in ***** rat cardiac fibroblasts.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.